446 related articles for article (PubMed ID: 25539046)
1. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.
Kumar S; Rao PS; Earla R; Kumar A
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):343-55. PubMed ID: 25539046
[TBL] [Abstract][Full Text] [Related]
2. An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.
Desai N; Burns L; Gong Y; Zhi K; Kumar A; Summers N; Kumar S; Cory TJ
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1005-1018. PubMed ID: 32842791
[TBL] [Abstract][Full Text] [Related]
3. Interactions between recreational drugs and antiretroviral agents.
Antoniou T; Tseng AL
Ann Pharmacother; 2002 Oct; 36(10):1598-613. PubMed ID: 12243611
[TBL] [Abstract][Full Text] [Related]
4. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084.
Cohn SE; Umbleja T; Mrus J; Bardeguez AD; Andersen JW; Chesney MA
AIDS Patient Care STDS; 2008 Jan; 22(1):29-40. PubMed ID: 18442305
[TBL] [Abstract][Full Text] [Related]
5. Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil.
Teixeira C; Dourado Mde L; Santos MP; Brites C
AIDS Res Hum Retroviruses; 2013 May; 29(5):799-804. PubMed ID: 23294471
[TBL] [Abstract][Full Text] [Related]
6. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.
Pal D; Kwatra D; Minocha M; Paturi DK; Budda B; Mitra AK
Life Sci; 2011 May; 88(21-22):959-71. PubMed ID: 20932495
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study.
Garin N; Zurita B; Velasco C; Feliu A; Gutierrez M; Masip M; Mangues MA
BMJ Open; 2017 Jan; 7(1):e014105. PubMed ID: 28100565
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy for drug users.
Clarke SM; Mulcahy FM
Int J STD AIDS; 2000 Oct; 11(10):627-31. PubMed ID: 11057932
[TBL] [Abstract][Full Text] [Related]
9. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse.
Wynn GH; Cozza KL; Zapor MJ; Wortmann GW; Armstrong SC
Psychosomatics; 2005; 46(1):79-87. PubMed ID: 15765827
[TBL] [Abstract][Full Text] [Related]
10. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.
Weber R; Huber M; Battegay M; Stähelin C; Castro Batanjer E; Calmy A; Bregenzer A; Bernasconi E; Schoeni-Affolter F; Ledergerber B;
HIV Med; 2015 Mar; 16(3):137-51. PubMed ID: 25124393
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.
Gong Y; Haque S; Chowdhury P; Cory TJ; Kodidela S; Yallapu MM; Norwood JM; Kumar S
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):417-427. PubMed ID: 30951643
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.
Lappalainen L; Nolan S; Dobrer S; Puscas C; Montaner J; Ahamad K; Dong H; Kerr T; Wood E; Milloy MJ
Addiction; 2015 Aug; 110(8):1330-9. PubMed ID: 25940906
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring in highly active antiretroviral therapy.
Liu X; Ma Q; Zhang F
Expert Opin Drug Saf; 2010 Sep; 9(5):743-58. PubMed ID: 20350281
[TBL] [Abstract][Full Text] [Related]
14. Alcohol and drug use severity are independently associated with antiretroviral adherence in the current treatment era.
Ma J; Luu B; Ruderman SA; Whitney BM; Merrill JO; Mixson LS; Nance RM; Drumright LN; Hahn AW; Fredericksen RJ; Chander G; Lau B; McCaul ME; Safren S; O'Cleirigh C; Cropsey K; Mayer KH; Mathews WC; Moore RD; Napravnik S; Christopoulos K; Willig A; Jacobson JM; Webel A; Burkholder G; Mugavero MJ; Saag MS; Kitahata MM; Crane HM; Delaney JAC
AIDS Care; 2024 May; 36(5):618-630. PubMed ID: 37419138
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America.
De Boni RB; Shepherd BE; Grinsztejn B; Cesar C; Cortés C; Padgett D; Gotuzzo E; Belaunzarán-Zamudio PF; Rebeiro PF; Duda SN; McGowan CC
AIDS Behav; 2016 Nov; 20(11):2692-2699. PubMed ID: 27091028
[TBL] [Abstract][Full Text] [Related]
17. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy.
Chander G; Himelhoch S; Moore RD
Drugs; 2006; 66(6):769-89. PubMed ID: 16706551
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems.
Kim TW; Palepu A; Cheng DM; Libman H; Saitz R; Samet JH
AIDS Care; 2007 Sep; 19(8):1039-47. PubMed ID: 17852002
[TBL] [Abstract][Full Text] [Related]
19. Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART).
Purohit V; Rapaka RS; Schnur P; Shurtleff D
Life Sci; 2011 May; 88(21-22):909-16. PubMed ID: 21477599
[TBL] [Abstract][Full Text] [Related]
20. Ageing with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C; Back D; Weber R; Furrer H; Cavassini M; Calmy A; Vernazza P; Bernasconi E; Khoo S; Battegay M; Elzi L;
J Antimicrob Chemother; 2011 Sep; 66(9):2107-11. PubMed ID: 21680580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
